Robert Hayman Net Worth

The estimated Net Worth of Robert Hayman is at least $343 Thousand dollars as of 9 September 2022. Mr. Hayman owns over 10,000 units of Evolus Inc stock worth over $152,700 and over the last 6 years he sold EOLS stock worth over $0. In addition, he makes $190,698 as Independent Director at Evolus Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Hayman EOLS stock SEC Form 4 insiders trading

Robert has made over 2 trades of the Evolus Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of EOLS stock worth $103,900 on 9 September 2022.

The largest trade he's ever made was buying 10,000 units of Evolus Inc stock on 9 September 2022 worth over $103,900. On average, Robert trades about 1,497 units every 0 days since 2018. As of 9 September 2022 he still owns at least 10,000 units of Evolus Inc stock.

You can see the complete history of Mr. Hayman stock trades at the bottom of the page.

Robert Hayman biography

Robert Hayman serves as Independent Director of the Company. Mr. Hayman served as a member of ALPHAEON’s board of directors since April 2014. Since 2011, Mr. Hayman has served as the owner and Chief Executive Officer of Hayman Properties, a real estate investment and development business. Since 2015, Mr. Hayman has served as Principal and Chief Executive Officer of Perimetrics, LLC, a dental diagnostic service company. Since April 2008, Mr. Hayman served as Principal at Common Sense Concepts, LLC, a dental device development company. From 1993 to February 2008, Mr. Hayman served as the co-founder, Chief Executive Officer and Chairman of Discus Dental, Inc. Mr. Hayman attended the masters degree program in Psychology at Pepperdine University, and received a B.S. in Business Administration from Boston University.

What is the salary of Robert Hayman?

As the Independent Director of Evolus Inc, the total compensation of Robert Hayman at Evolus Inc is $190,698. There are 11 executives at Evolus Inc getting paid more, with Michael Jafar having the highest compensation of $3,929,160.

How old is Robert Hayman?

Robert Hayman is 61, he's been the Independent Director of Evolus Inc since 2018. There are 3 older and 8 younger executives at Evolus Inc. The oldest executive at Evolus Inc is Peter Farrell, 78, who is the Independent Director.

What's Robert Hayman's mailing address?

Robert's mailing address filed with the SEC is 520 Newport Center Dr #1200, Newport Beach, CA 92660, USA.

Insiders trading at Evolus Inc

Over the last 7 years, insiders at Evolus Inc have traded over $244,915,132 worth of Evolus Inc stock and bought 3,308,677 units worth $53,545,237 . The most active insiders traders include Biopharma, Inc. Aeon, Inc. Medytox, and 1 Llc Alphaeon. On average, Evolus Inc executives and independent directors trade stock every 25 days with the average trade being worth of $3,606,270. The most recent stock trade was executed by Sandra Beaver on 6 September 2024, trading 3,276 units of EOLS stock currently worth $49,074.

What does Evolus Inc do?

evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.

Complete history of Mr. Hayman stock trades at Evolus Inc

Evolus Inc executives and stock owners

Evolus Inc executives and other stock owners filed with the SEC include:

• Michael Jafar,
  Chief Commercial Officer
• David Moatazedi,
  President, Chief Executive Officer, Director
• Rui Avelar,
  Chief Medical Officer, Head of Research & Development
• David Moatazedi,
  Pres, CEO & Director
• Lauren Silvernail,
  Chief Financial Officer, Executive Vice President - Corporate Development
• Lauren P. Silvernail,
  CFO & Exec. VP of Corp. Devel.
• Dr. Rui Avelar Dip.SportMed, M.D., C.CFP,
  Chief Medical Officer and Head of R&D
• Karah Parschauer,
  Independent Director
• Peter Farrell,
  Independent Director
• Vikram Malik,
  Chairman of the Board
• David Gill,
  Independent Director
• Robert Hayman,
  Independent Director
• Simone Blank,
  Director
• Tram Bui,
  IR Contact Officer
• Jeff Plumer,
  General Counsel
• Jessica Novak,
  Sr. VP of HR
• Crystal Muilenburg,
  Chief Marketing Officer
• Kurt Knab,
  VP of Sales
• Jeffrey J. Plumer,
  Gen. Counsel
• David K. Erickson,
  VP of Investor Relations
• Biopharma, Inc. Aeon,
  
• Sandra Beaver,
  Chief Financial Officer
• Crystal Muilenburg,
  Chief Marketing Officer
• Albert G Iii White,
  Director
• Kristine Romine,
  Director
• Bosun Hau,
  Director
• 1 Llc Alphaeon,
  
• Brady Stewart,
  Director
• Tomoko Yamagishi Dressler,
  Chief Marketing Officer
• Inc. Medytox,